Key Findings
The North America ophthalmic drugs market is projected to record a CAGR of 5.56% during the forecast period, 2023-2032. Growing awareness of eye health and the accessibility of eye care services are fostering early detection and treatment of eye conditions. This pattern is fueling the expansion of the ophthalmic drugs market in North America.

Market Insights
Canada and the United States are evaluated for the North America ophthalmic drugs market growth assessment. The surge in eye diseases, particularly those associated with aging and lifestyle, is fueling the need for ophthalmic drugs. Progress in drug delivery technologies is amplifying drug effectiveness and patient adherence, contributing to market expansion. With an increasing elderly population in the United States, there is a heightened vulnerability to age-related eye conditions, driving up the demand for ophthalmic drugs. The pharmaceutical industry’s dedication to research and development is yielding the creation of advanced ophthalmic drugs, marking a significant stride forward.
The ophthalmic drugs market in the United States is dominated by key players such as Novartis AG, Allergan (now a part of AbbVie Inc), Regeneron Pharmaceuticals, Santen Pharmaceutical Co Ltd, and Bausch Health Companies Inc. These industry leaders consistently invest in research and development, aiming to introduce novel and advanced ophthalmic drugs to the market. This ongoing commitment plays a pivotal role in fostering the growth and progression of eye care in the United States.

Competitive Insights
Some of the leading players in the North America ophthalmic drugs market include Bausch Health Companies Inc, Pfizer Inc, AbbVie Inc, etc.
Our report offerings include:

  • Explore key findings of the overall market
  • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
  • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
  • Market Segmentation caters to a thorough assessment of key segments with their market estimations
  • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
  • Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
  • The competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
  • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments